Bayer (BAYN) AI Stock Analysis

Top Page

Bayer

(XETRA:BAYN)

Select Model

Rating:57Neutral

Price Target:EUR 46.00▼(-9.05% Downside)

Action:reiterated

Date:08/10/26

The score is held back primarily by weak financial performance (multi-year net losses, inconsistent operating profitability, and historically elevated leverage), partially offset by continued positive—though volatile—free cash flow. Technicals are a key support with a clear uptrend and positive momentum indicators. Valuation is mixed: a high dividend yield helps, but the negative P/E underscores that current earnings are under pressure.

Positive Factors

Diversified Life-Sciences ModelBayer’s presence in both healthcare and agriculture gives it multiple end markets, product categories, and sources of revenue. This diversification can reduce reliance on one therapeutic area or crop cycle and provides a broader platform for deploying research, brands, and distribution capabilities over time.

Negative Factors

Persistent Net LossesSustained net losses and weak operating profitability show that solid gross margins are not translating into dependable earnings. This constrains internally funded growth, reduces resilience against additional operating pressures, and raises uncertainty about when the underlying portfolio will produce consistently attractive returns.

Bayer (BAYN) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 49.69B
Dividend Yield: 0.22%
Average Volume (3M): 2.14M
Price to Earnings (P/E): -28.7
Beta (1Y): 1.14
Revenue Growth: -1.73%
EPS Growth: 49.15%
Country: Germany
Employees: 87,830
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - General

Bayer Business Overview & Revenue Model

Company Description

Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer...

How the Company Makes Money

Bayer makes money mainly by selling products and related services through two primary segments: Pharmaceuticals and Crop Science. 1) Pharmaceuticals revenue model - Prescription medicines: Bayer generates revenue from the sale of branded prescription...

Bayer Financial Statement Overview

Summary

Financials are mixed: revenue has been flat-to-down over several years with a rebound in TTM, but profitability is the core weakness with net losses from 2023 through TTM and inconsistent/low operating margins. Cash generation is a relative positive (positive operating cash flow and free cash flow), though free cash flow is volatile with a sharp TTM drop. Balance-sheet leverage has been a multi-year constraint (debt above equity historically) and ROE is negative in recent periods, limiting financial flexibility.

Income Statement

36Negative

Balance Sheet

48Neutral

Cash Flow

55Neutral

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	45.38B	45.58B	46.61B	47.64B	50.74B	44.08B
Gross Profit	26.80B	26.98B	25.34B	27.89B	30.87B	27.27B
EBITDA	5.08B	2.65B	3.67B	4.05B	10.29B	7.02B
Net Income	-1.74B	-3.62B	-2.55B	-2.94B	4.15B	1.00B
Balance Sheet
Total Assets	107.28B	110.61B	110.85B	116.26B	124.88B	120.24B
Cash, Cash Equivalents and Short-Term Investments	5.08B	7.86B	8.09B	10.59B	10.15B	7.74B
Total Debt	38.43B	37.44B	40.74B	44.79B	41.65B	39.53B
Total Liabilities	77.58B	84.54B	78.81B	83.18B	85.95B	87.07B
Stockholders Equity	29.58B	25.95B	31.91B	32.93B	38.77B	33.02B
Cash Flow
Free Cash Flow	1.45B	2.08B	4.59B	2.37B	4.14B	2.48B
Operating Cash Flow	4.16B	4.57B	7.37B	5.12B	7.09B	5.09B
Investing Cash Flow	-2.18B	-1.61B	164.00M	-4.01B	-2.38B	855.00M
Financing Cash Flow	-2.31B	-2.19B	-7.18B	-679.00M	-4.22B	-5.64B

Bayer Technical Analysis

Technical Analysis SentimentPositive

Last Price50.58

Price Trends

50DMA47.19Positive

100DMA47.01Positive

200DMA43.54Positive

Market Momentum

MACD0.17Negative

RSI69.50Neutral

STOCH96.20Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:BAYN, the sentiment is Positive. The current price of 50.58 is above the 20-day moving average (MA) of 44.83, above the 50-day MA of 47.19, and above the 200-day MA of 43.54, indicating a bullish trend. The MACD of 0.17 indicates Negative momentum. The RSI at 69.50 is Neutral, neither overbought nor oversold. The STOCH value of 96.20 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:BAYN.

Bayer Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

DE:BAYN against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DE:BEI	77Outperform	EUR 17.68B	19.30	10.66%	1.20%	-2.50%	8.61%
DE:AFX	73Outperform	EUR 3.13B	20.95	5.52%	1.57%	-0.06%	-38.81%
DE:BAS	69Neutral	EUR 47.71B	8.04	16.48%	4.21%	-3.87%	2071.79%
DE:BAYN	57Neutral	EUR 49.69B	-28.74	-6.10%	0.22%	-1.73%	49.15%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
DE:COP	53Neutral	EUR 1.50B	43.42	4.19%	1.74%	―	―

* General Sector Average

Performance Comparison

DE:BAYN and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:BAYN	Bayer Ag (UK)	50.58	24.19	91.63%
DE:BAS	BASF SE (UK)	53.46	12.30	29.87%
DE:BEI	Beiersdorf AG	82.80	-7.47	-8.27%
DE:AFX	Carl Zeiss Meditec	34.98	-7.07	-16.82%
DE:COP	CompuGroup Medical	28.45	4.30	17.83%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 10, 2026

Bayer AI Stock Analysis